Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer. 2022

Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Chang Gung University College of Medicine, Taoyuan, Taiwan; Gynecologic Cancer Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Institute of Biomedical Engineering, International Intercollegiate Ph.D. Program, National Tsing Hua University, Hsinchu, Taiwan; Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan.

To investigate outcomes and morbidity of patients undergoing secondary cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent ovarian cancer. Between April 2014 and January 2019, a total of 51 recurrent ovarian cancer patients receiving secondary CRS and HIPEC were retrospectively reviewed. Among the 51 patients, median peritoneal cancer index score was 13 (range 3-34), and completeness of cytoreduction (CC) score of 0/1 was achieved in 41 patients (78.8%). Regimen of HIPEC included cisplatin and paclitaxel in 39 (75%) cases. The median follow-up duration of survivors was 20.2 months. Sixteen (30.8%) patients remained free of recurrence after HIPEC. The median progression-free survival (PFS) and overall survival (OS) were 11.8 months and 34.5 months respectively. Multivariate analysis showed previous chemotherapy <2 lines (HR 0.24, 0.11-0.52; p = 0.001), chemotherapy-free interval ≥6 months (HR 0.19, 0.09-0.37; p < 0.001) and CA125 < 35 U/mL before HIPEC (HR 0.133, 0.021-0.0832; p = 0.031) were good prognostic factors for PFS. CC0/1 was not significant in multivariate analysis. The most common grade 3/4 toxicity was anemia (17.3%), pleural effusion (11.5%) and renal insufficiency (5.7%). Patients with age ≥50, peritoneal carcinomatosis index (PCI) ≥ 11, operation time ≥10 h and diaphragm surgery had significantly higher incidence of pleural effusion. The current study showed adding HIPEC to secondary CRS might prolong PFS especially in patients with previous chemotherapy <2 lines, chemotherapy-free interval ≥6 months and CA125 < 35 U/mL before HIPEC.

UI MeSH Term Description Entries
D006979 Hyperthermia, Induced Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs. Fever Therapy,Hyperthermia, Local,Hyperthermia, Therapeutic,Thermotherapy,Induced Hyperthermia,Therapeutic Hyperthermia,Therapy, Fever,Local Hyperthermia
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010534 Peritoneal Neoplasms Tumors or cancer of the PERITONEUM. Peritoneal Carcinomatosis,Peritoneal Surface Malignancy,Carcinomatosis, Peritoneal,Malignancy, Peritoneal Surface,Neoplasm, Peritoneal,Peritoneal Carcinomatoses,Peritoneal Neoplasm,Peritoneal Surface Malignancies,Surface Malignancy, Peritoneal
D010996 Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself. Effusion, Pleural,Effusions, Pleural,Pleural Effusions
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077216 Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer. Epithelial Ovarian Cancer,Epithelial Ovarian Carcinoma,Ovarian Cancer, Epithelial,Ovarian Epithelial Cancer,Ovarian Epithelial Carcinoma,Cancer, Epithelial Ovarian,Cancer, Ovarian Epithelial,Carcinoma, Epithelial Ovarian,Epithelial Cancer, Ovarian,Epithelial Carcinoma, Ovarian,Epithelial Ovarian Cancers,Epithelial Ovarian Carcinomas,Ovarian Carcinoma, Epithelial,Ovarian Epithelial Cancers,Ovarian Epithelial Carcinomas
D000084262 Hyperthermic Intraperitoneal Chemotherapy A cancer treatment that involves filling the abdominal cavity with heated chemotherapy drugs. It is performed after the surgeon removes tumors or lesions from the abdominal area, to kill any cancer cells that remain after surgery and reduce the risk for cancer recurrence. (From: https://www.mdanderson.org/treatment-options/hyperthermic-intraperitoneal-chemotherapy.html; Feb, 20, 2020). HIPEC,Hot Chemotherapy,Intraperitoneal Hyperthermic Chemotherapy,Chemotherapy, Hot,Chemotherapy, Hyperthermic Intraperitoneal,Chemotherapy, Intraperitoneal Hyperthermic,Hyperthermic Chemotherapy, Intraperitoneal,Intraperitoneal Chemotherapy, Hyperthermic,Intraperitoneal Hyperthermic Chemotherapies

Related Publications

Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
November 2002, Ginekologia polska,
Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
January 2014, Voprosy onkologii,
Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
May 2022, JAMA surgery,
Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
September 2019, Indian journal of surgical oncology,
Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
December 2022, Gynecologic oncology,
Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
August 2021, JAAPA : official journal of the American Academy of Physician Assistants,
Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
June 2012, BJOG : an international journal of obstetrics and gynaecology,
Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
April 2018, The New England journal of medicine,
Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
April 2018, The New England journal of medicine,
Wei-Chun Chen, and Huei-Jean Huang, and Lan-Yan Yang, and Yu-Bin Pan, and Kuan-Gen Huang, and Cheng-Tao Lin, and Min-Yu Chen, and Yun-Hsin Tang, and Ting-Chang Chang, and Chyong-Huey Lai, and Hung-Hsueh Chou
April 2018, The New England journal of medicine,
Copied contents to your clipboard!